Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Assets (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Assets data on record, last reported at $2.4 billion in Q4 2025.

  • For Q4 2025, Assets fell 7.97% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $2.4 billion, down 7.97%, while the annual FY2025 figure was $2.4 billion, 7.97% down from the prior year.
  • Assets reached $2.4 billion in Q4 2025 per RVMD's latest filing, up from $2.3 billion in the prior quarter.
  • Across five years, Assets topped out at $2.6 billion in Q4 2024 and bottomed at $632.8 million in Q2 2022.
  • Average Assets over 5 years is $1.4 billion, with a median of $1.1 billion recorded in 2023.
  • Peak YoY movement for Assets: fell 18.25% in 2022, then soared 153.93% in 2023.
  • A 5-year view of Assets shows it stood at $738.0 million in 2021, then rose by 10.02% to $811.9 million in 2022, then skyrocketed by 153.93% to $2.1 billion in 2023, then rose by 24.09% to $2.6 billion in 2024, then decreased by 7.97% to $2.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $2.4 billion in Q4 2025, $2.3 billion in Q3 2025, and $2.4 billion in Q2 2025.